Robert Motzer

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, NY
    N Engl J Med 370:1769-70. 2014
  2. pmc Targeted therapy for metastatic renal cell carcinoma
    P H Patel
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Br J Cancer 94:614-9. 2006
  3. ncbi request reprint Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, NY, USA Electronic address
    Lancet Oncol 15:286-96. 2014
  4. pmc Dynamic tumor modeling of the dose-response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial
    Andrew Stein
    Modeling and Simulation, Novartis Institutes for BioMedical Research, 45 Sidney St, Cambridge, MA, USA
    BMC Cancer 12:311. 2012
  5. doi request reprint Pazopanib versus sunitinib in metastatic renal-cell carcinoma
    Robert J Motzer
    Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    N Engl J Med 369:722-31. 2013
  6. pmc Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
    R J Motzer
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Br J Cancer 108:2470-7. 2013
  7. ncbi request reprint Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, NY, USA Electronic address
    Lancet Oncol 14:552-62. 2013
  8. ncbi request reprint Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 30:1371-7. 2012
  9. pmc Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
    Ana M Molina
    Genitourinary Service, Division of Medical Oncology and the Department of Medical Imaging, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Med Oncol 28:1527-9. 2011
  10. pmc Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins
    Samuel E DePrimo
    Translational Medicine, Pfizer Global Research and Development, La Jolla, CA, USA
    J Transl Med 5:32. 2007

Detail Information

Publications101 found, 100 shown here

  1. ncbi request reprint Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, NY
    N Engl J Med 370:1769-70. 2014
    ..Survival results are now mature for a noninferiority trial comparing pazopanib with sunitinib in renal-cell carcinoma. Median survival was 42.5 months with pazopanib and 43.6 months with sunitinib, a difference that wasnot significant. ..
  2. pmc Targeted therapy for metastatic renal cell carcinoma
    P H Patel
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Br J Cancer 94:614-9. 2006
    ..The results of phase III studies will determine the role of these agents in metastatic RCC...
  3. ncbi request reprint Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, NY, USA Electronic address
    Lancet Oncol 15:286-96. 2014
    ..Dovitinib is an oral tyrosine-kinase inhibitor that inhibits VEGF and FGF receptors. We therefore compared dovitinib with sorafenib as third-line targeted therapies in patients with metastatic renal cell carcinoma...
  4. pmc Dynamic tumor modeling of the dose-response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial
    Andrew Stein
    Modeling and Simulation, Novartis Institutes for BioMedical Research, 45 Sidney St, Cambridge, MA, USA
    BMC Cancer 12:311. 2012
    ..We have developed a model of tumor growth dynamics utilizing serial measurements of the sum of the longest tumor diameters (SLD) from individual RECORD-1 patients to define the dose-response relationship of everolimus...
  5. doi request reprint Pazopanib versus sunitinib in metastatic renal-cell carcinoma
    Robert J Motzer
    Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    N Engl J Med 369:722-31. 2013
    ..This phase 3, randomized trial compared the efficacy and safety of pazopanib and sunitinib as first-line therapy...
  6. pmc Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
    R J Motzer
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Br J Cancer 108:2470-7. 2013
    ..Prognostic factors for progression-free survival (PFS), overall survival (OS), and long-term OS (≥30 months) were investigated in sunitinib-treated patients with metastatic renal cell carcinoma (RCC)...
  7. ncbi request reprint Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, NY, USA Electronic address
    Lancet Oncol 14:552-62. 2013
    ..Here, we report overall survival and updated efficacy, quality of life, and safety results...
  8. ncbi request reprint Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 30:1371-7. 2012
    ..A trial was conducted to compare the schedules...
  9. pmc Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
    Ana M Molina
    Genitourinary Service, Division of Medical Oncology and the Department of Medical Imaging, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Med Oncol 28:1527-9. 2011
    ....
  10. pmc Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins
    Samuel E DePrimo
    Translational Medicine, Pfizer Global Research and Development, La Jolla, CA, USA
    J Transl Med 5:32. 2007
    ....
  11. pmc A brief symptom index for advanced renal cell carcinoma
    David T Eton
    Center on Outcomes, Research and Education, Evanston Northwestern Healthcare, 1001 University Place, Suite 100, Evanston IL 60201, USA
    Health Qual Life Outcomes 4:68. 2006
    ..Our objective was to test a brief, symptom index for advanced renal cell carcinoma, a disease affecting over 38,000 Americans each year and often diagnosed in late stages...
  12. doi request reprint Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma
    Robert J Motzer
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 113:1552-8. 2008
    ..On the basis of outcome data from that trial, the authors developed a nomogram for predicting the probability of 12-month progression-free survival for patients who received sunitinib therapy...
  13. ncbi request reprint Targeted therapy for metastatic renal cell carcinoma
    Robert J Motzer
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, The Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:5601-8. 2006
    ..Sunitinib and sorafenib were recently approved by the US Food and Drug Administration for treatment of mRCC, These drugs are currently included in clinical practice...
  14. ncbi request reprint Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma
    Robert J Motzer
    Geritourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 22:454-63. 2004
    ..To describe survival in previously treated patients with metastatic renal cell carcinoma (RCC) who are candidates for clinical trials of new agents as second-line therapy...
  15. ncbi request reprint Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy
    G Varuni Kondagunta
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 22:464-7. 2004
    ....
  16. ncbi request reprint Predicting survival of patients with metastatic renal cell carcinoma
    R J Motzer
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Urologe A 43:S135-6. 2004
    ..Prospective identification of patients more likely to benefit from cytokine therapy is important as a stratification factor in phase III trials, and in risk-directed therapy...
  17. pmc Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Clin Genitourin Cancer 7:28-33. 2009
    ..Herein, we report the results of a phase I dose-finding study of sunitinib in combination with IFN-alpha as first-line treatment in patients with metastatic RCC...
  18. pmc Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 27:3584-90. 2009
    ..Final survival analyses and updated results are reported...
  19. ncbi request reprint Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
    Robert J Motzer
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:16-24. 2006
    ..SU11248 (sunitinib malate), a small molecule inhibitor with high binding affinity for VEGF and PDGF receptors, was tested for clinical activity in patients with metastatic RCC...
  20. doi request reprint Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Clin Oncol 33:614-8. 2010
    ..This phase I/II study investigated sunitinib in combination with an epidermal growth factor receptor inhibitor, gefitinib, in patients with metastatic RCC...
  21. ncbi request reprint Sunitinib malate for the treatment of solid tumours: a review of current clinical data
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Expert Opin Investig Drugs 15:553-61. 2006
    ..Sunitinib has also demonstrated promising clinical activity in the treatment of other advanced solid tumours. The present review provides an updated summary of emerging clinical experience with this promising new anticancer agent...
  22. ncbi request reprint Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors
    Robert J Motzer
    Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 116:4256-65. 2010
    ..Final results and analysis of prognostic factors are reported...
  23. ncbi request reprint Sunitinib in patients with metastatic renal cell carcinoma
    Robert J Motzer
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    JAMA 295:2516-24. 2006
    ..Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor, which has shown activity in an initial study of cytokine-refractory metastatic RCC patients...
  24. ncbi request reprint Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients
    R J Motzer
    Genitourinary Oncology, Nuclear Medicine, and Renal Services, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 18:1173-80. 2000
    ..Carboplatin was dose escalated by target area under the curve (AUC; in [milligrams per milliliter] x minutes) among patient cohorts, and pharmacokinetic studies were performed for comparison...
  25. ncbi request reprint Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:3958-64. 2007
    ..A recommended dose and safety profile for the combination of temsirolimus and interferon alfa (IFN) were determined in patients with advanced RCC...
  26. ncbi request reprint Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
    Robert J Motzer
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 20:289-96. 2002
    ..The data can be applied to design and interpretation of clinical trials of new agents and treatment programs against this refractory malignancy...
  27. ncbi request reprint Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma
    R J Motzer
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Interferon Cytokine Res 21:257-63. 2001
    ..Further study of rHuIL-12 for other medical conditions is underway. For RCC, the study of new cytokines is of the highest priority...
  28. ncbi request reprint Targeted drugs for metastatic renal cell carcinoma
    Robert J Motzer
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet 370:2071-3. 2007
  29. ncbi request reprint Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors
    Robert J Motzer
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:247-56. 2007
    ..Serum tumor marker decline during chemotherapy was assessed prospectively as a predictor of treatment outcome...
  30. ncbi request reprint Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    N Engl J Med 356:115-24. 2007
    ..Since sunitinib malate has shown activity in two uncontrolled studies in patients with metastatic renal-cell carcinoma, a comparison of the drug with interferon alfa in a phase 3 trial is warranted...
  31. ncbi request reprint Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology
    Robert J Motzer
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:2376-81. 2002
    ..To define outcome data for patients with metastatic renal cell carcinoma (RCC) with histology other than clear-cell type, including collecting duct (or medullary carcinoma), papillary, chromophobe, and unclassified histologies...
  32. ncbi request reprint Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma
    R J Motzer
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Oncol 13:1799-805. 2002
    ..A phase II trial was conducted in previously untreated patients with advanced renal cell carcinoma (RCC) to assess efficacy, toxicity and pharmacokinetic profile...
  33. ncbi request reprint Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet 372:449-56. 2008
    ..We did a phase III, randomised, double-blind, placebo-controlled trial of everolimus in patients with metastatic renal cell carcinoma whose disease had progressed on vascular endothelial growth factor-targeted therapy...
  34. ncbi request reprint Prognostic factors and clinical trials of new agents in patients with metastatic renal cell carcinoma
    Robert J Motzer
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Crit Rev Oncol Hematol 46:S33-9. 2003
    ..Prospective identification of patients more likely to benefit from cytokine therapy could be used as a stratification factor in Phase III trials, and in risk-directed therapy...
  35. ncbi request reprint Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma
    Robert J Motzer
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 21:99-101. 2003
    ..The lack of clinical response or suggestion of prolonging time to progression compared to historical data with interferon-alfa supports no further study of single-agent C225 in patients with metastatic RCC...
  36. pmc Body mass index is associated with higher lymph node counts during retroperitoneal lymph node dissection
    R Houston Thompson
    Department of Surgery Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Urology 79:361-4. 2012
    ..Lymph node counts are a proposed measure of quality assurance for numerous malignancies. Investigation of patient factors associated with lymph node counts are lacking...
  37. ncbi request reprint Cluster analysis of p53 and Ki67 expression, apoptosis, alpha-fetoprotein, and human chorionic gonadotrophin indicates a favorable prognostic subgroup within the embryonal carcinoma germ cell tumor
    Madhu Mazumdar
    Memorial Sloan Kettering Cancer Center, 307 E 63rd St, 3rd Floor, New York, NY 10021, USA
    J Clin Oncol 21:2679-88. 2003
    ..We sought to determine whether simultaneous expression of one or more of these markers could identify clinically relevant subgroups of patients with nonseminomatous GCT (NSGCT)...
  38. pmc Contemporary lymph node counts during primary retroperitoneal lymph node dissection
    R Houston Thompson
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Urology 77:368-72. 2011
    ..We report our contemporary single-surgeon experience with lymph node counts during primary RPLND for nonseminomatous germ cell tumors...
  39. ncbi request reprint A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma
    Maximiliano Sorbellini
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Urol 173:48-51. 2005
    ..We developed and performed external validation of a postoperative nomogram for this purpose. We used a prospectively updated database of more than 1,400 patients treated at a single institution...
  40. ncbi request reprint Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma
    Beverly Drucker
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 21:341-5. 2003
    ..At the dose and schedule used in this trial, the lack of antitumor activity associated with ZD1839 does not support further study in patients with metastatic RCC...
  41. pmc A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
    Ana M Molina
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
    Cancer Chemother Pharmacol 73:181-9. 2014
    ..This phase 1b study assessed safety, maximum tolerated dose (MTD), and preliminary antitumor activity of lenvatinib plus everolimus in metastatic RCC (mRCC) patients...
  42. pmc Evaluation of lymph node counts in primary retroperitoneal lymph node dissection
    R Houston Thompson
    Department of Surgery Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cancer 116:5243-50. 2010
    ..Lymph node counts are a measure of quality assurance and are associated with prognosis for numerous malignancies. To date, investigations of lymph node counts in testis cancer are lacking...
  43. doi request reprint Outcomes after resection of postchemotherapy residual neck mass in patients with germ cell tumors--an update
    Amit Gupta
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Urology 77:655-9. 2011
    ..To examine histologic findings and clinical outcomes of patients who underwent neck dissection for residual neck masses...
  44. ncbi request reprint Partial nephrectomy: the rationale for expanding the indications
    Paul Russo
    Department of Urology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg Oncol 9:680-7. 2002
    ..We report preliminary results of partial nephrectomy for renal tumors of > or =4 cm in 39 patients with the intent of extending the indications for kidney-sparing surgery...
  45. ncbi request reprint Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer
    Paul Russo
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    ScientificWorldJournal 7:768-78. 2007
    ..This surgical experience provides a contemporary foundation as new targeted therapeutic agents are integrated into the neoadjuvant or adjuvant treatment of locally advanced and metastatic renal cancer...
  46. ncbi request reprint Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum
    J Vuky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 19:682-8. 2001
    ..Because patients who undergo conventional salvage chemotherapy programs rarely achieve long-term disease-free status, selected patients with elevated markers after chemotherapy are considered candidates for surgical resection...
  47. ncbi request reprint Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy
    M Mazumdar
    Department of Epidemiology and Biostatistics and the Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 19:2534-41. 2001
    ..We re-examined this issue in the context of the International Germ Cell Cancer Collaborative Group (IGCCCG) risk classification system and investigated the role of including in the analysis patients whose markers normalized early...
  48. ncbi request reprint Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma
    R J Motzer
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 19:1312-9. 2001
    ..PEG-IFN is more convenient to administer than IFNalpha and has potential for increased efficacy, less toxicity, or both. The efficacy and toxicity of PEG-IFN will be further assessed in clinical trials and compared with IFNalpha...
  49. ncbi request reprint Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival
    J A McCaffrey
    Department of Medicine, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, New York, NY 10021, USA
    J Clin Oncol 15:2559-63. 1997
    ..To evaluate the efficacy and toxicity of ifosfamide- and cisplatin-containing chemotherapy as first-line salvage treatment for patients with germ cell tumors (GCT)...
  50. ncbi request reprint A postoperative prognostic nomogram for renal cell carcinoma
    M W Kattan
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    J Urol 166:63-7. 2001
    ..The nomogram may be useful for patient counseling, clinical trial design and patient followup planning...
  51. ncbi request reprint Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse
    F Rabbani
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 19:2020-5. 2001
    ..In contrast, patients with elevated markers before retroperitoneal lymphadenectomy have a high rate of relapse and should be considered for primary chemotherapy...
  52. pmc Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations
    Christoph A Karlo
    From the Genitourinary Imaging Group, Department of Radiology C A K, P L D P, J C, H H, O A, Urology Service, Department of Surgery A A H, P R, Human Oncology and Pathogenesis Program A A H, J J H, Department of Epidemiology and Biostatistics I O, and Department of Medicine, Genitourinary Oncology Service R M, J J H, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Radiology Academic Offices, Room C278, New York, NY 10065
    Radiology 270:464-71. 2014
    ..To investigate associations between computed tomographic (CT) features of clear cell renal cell carcinoma (RCC) and mutations in VHL, PBRM1, SETD2, KDM5C, or BAP1 genes...
  53. pmc Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma
    Michael J Zelefsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 82:1744-8. 2012
    ..To report tumor local progression-free outcomes after treatment with single-dose, image-guided, intensity-modulated radiotherapy and hypofractionated regimens for extracranial metastases from renal cell primary tumors...
  54. ncbi request reprint The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers
    J Bacik
    Department of Epidemiology and Biostatistics a Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Qual Life Res 13:137-54. 2004
    ..This paper reports on the development and validation of two biologic response modifier (BRM) subscales for use with the Functional Assessment of Cancer Therapy-General (FACT-G) quality of life (QOL) questionnaire...
  55. ncbi request reprint Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma
    W J Berg
    Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 19:317-20. 2001
    ..Eight patients had stable disease as best response. Toxicity included myelosuppression and gastrointestinal side effects. At the dose and schedule used in this trial, irofulven did not produce clinical response in RCC...
  56. pmc Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow
    Ana M Molina
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncologist 16:45-50. 2011
    ..Because clinical trial populations may not represent real-life patient populations, recommendations should serve only as a guide and must be tailored to the needs of each patient...
  57. ncbi request reprint Blood group-related antigens in human germ cell tumors
    R J Motzer
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
    Cancer Res 48:5342-7. 1988
    ..If so, it is possible that the heterogeneous expression of blood group substances in seminomas with atypical histologies is an indication of differentiation towards nonseminomatous germ cell tumor...
  58. ncbi request reprint Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma
    Premal H Patel
    Genitourinary Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 26:273-6. 2008
    ..Toxicities included fatigue, hyperglycemia, dyspnea, and myelosuppression with decreased hemoglobin, lymphopenia, and neutropenia. Lenalidomide is tolerable, but no objective responses were observed in this clinical trial...
  59. ncbi request reprint Phase II trial of thalidomide for patients with advanced renal cell carcinoma
    Robert J Motzer
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 20:302-6. 2002
    ..To assess efficacy and toxicity of thalidomide in patients with advanced renal cell carcinoma (RCC)...
  60. doi request reprint The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor
    Atreya Dash
    Department of Urology and Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 112:800-5. 2008
    ..The objectives of the current study were to determine the clinical outcome, patterns of relapse, and incidence of teratoma in the retroperitoneum for men with cIS NSGCT...
  61. doi request reprint Medical treatment of advanced testicular cancer
    Darren R Feldman
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    JAMA 299:672-84. 2008
    ..Clinicians need to be familiar with the available treatment regimens for testicular cancer and their associated toxic effects...
  62. doi request reprint Sunitinib therapy in renal cell carcinoma
    Matthew F O'Brien
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 101:1339-42. 2008
  63. doi request reprint Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors
    Ashwin Jathavedam
    Infectious Disease Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Biol Blood Marrow Transplant 14:595-600. 2008
    ..In conclusion, serious morbidity from infection is uncommon among GCT patients receiving high-dose chemotherapy with ASCT. Isolation and aggressive antifungal and antiviral prophylaxis is not warranted in these patients...
  64. doi request reprint Stage I testicular cancer management and necessity for surgical expertise
    Joel Sheinfeld
    J Clin Oncol 26:2934-6. 2008
  65. pmc Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma
    Scott E Eggener
    Department of Urology and Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 180:873-8; discussion 878. 2008
    ..We evaluated the prognostic roles of metastasectomy and an established risk stratification system in patients with disease recurrence following nephrectomy for nonmetastatic renal cell carcinoma...
  66. ncbi request reprint Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial
    David Cella
    Center on Outcomes, Research and Education, Evanston Northwestern Healthcare and Northwestern University Feinberg School of Medicine, 1001 University Place, Evanston, IL 60201, USA
    J Clin Oncol 26:3763-9. 2008
    ..001; objective response rate, 31% v 6%, respectively; P < .001). We report health-related quality-of-life (QOL) results from this trial...
  67. ncbi request reprint Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma
    Edit Remak
    Health Care Analytics, United BioSource Corp, 20 Bloomsbury Square, London WC1A 2NS, United Kingdom
    J Clin Oncol 26:3995-4000. 2008
    ..To assess the cost effectiveness and cost utility of sunitinib malate as a first-line treatment in metastatic renal cell carcinoma (mRCC) compared with interferon-alfa (IFN-alpha) and interleukin-2 (IL-2) from a US societal perspective...
  68. ncbi request reprint Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors
    Brett S Carver
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, 353 E 68th St, New York, NY 10021, USA
    J Clin Oncol 25:5603-8. 2007
    ..We evaluated men undergoing postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for NSGCT to determine associations between year of treatment and clinical outcome...
  69. ncbi request reprint Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study
    Olivier Rixe
    Pitie Salpetriere Hospital, University of Paris, Paris, France
    Lancet Oncol 8:975-84. 2007
    ..We aimed to assess the activity and safety of axitinib in patients with metastatic renal-cell cancer who had failed on previous cytokine-based treatment...
  70. ncbi request reprint Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy
    Ellen A Ronnen
    Department of Medicine, Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 23:6999-7004. 2005
    ..To define the incidence, clinical features, and outcome to salvage chemotherapy in patients with late-relapse germ cell tumor (GCT) after a complete response to first-line chemotherapy...
  71. ncbi request reprint Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development
    Brian I Rini
    Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    BJU Int 96:286-90. 2005
  72. ncbi request reprint Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion
    Andrew J Stephenson
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers and Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 174:557-60; discussion 560. 2005
    ....
  73. ncbi request reprint Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome
    Andrew J Stephenson
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:2781-8. 2005
    ..Since 1999, our criteria have excluded patients with persistent postorchiectomy elevation of serum tumor markers (STM) or clinical stage (CS) IIB disease from RPLND...
  74. ncbi request reprint Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors
    G Varuni Kondagunta
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 22:177-9. 2004
    ..No patient experienced a grade 3 or 4 toxicity, and none of the 14 evaluable patients achieved a complete or partial response. Temozolomide is not efficacious in the treatment of cisplatin-refractory GCT patients...
  75. ncbi request reprint Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma
    Stephen D W Beck
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg Oncol 11:71-7. 2004
    ..Using a large renal tumor database, we examined the effect of tumor histology on the pattern of metastasis and patient survival...
  76. ncbi request reprint Clinical outcome after retroperitoneal lymphadenectomy of patients with pure testicular teratoma
    Farhang Rabbani
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 62:1092-6. 2003
    ..To determine the pathologic findings and clinical outcome of patients with pure teratoma of the testis who underwent primary or postchemotherapy retroperitoneal lymphadenectomy (RPLND)...
  77. ncbi request reprint Poor-risk testicular cancer and high-dose chemotherapy
    Robert J Motzer
    J Clin Oncol 21:4073-4. 2003
  78. ncbi request reprint Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome
    James M McKiernan
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 62:732-6. 2003
    ....
  79. ncbi request reprint Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials
    Lawrence H Schwartz
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 98:1611-9. 2003
    ....
  80. ncbi request reprint Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIA nonseminomatous germ cell tumors
    Joel Sheinfeld
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 170:1159-62. 2003
    ..We determined the incidence and clinical outcome of patients with clinical stages I and IIA nonseminomatous germ cell tumors (NSGCT), and teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection (RPLND)...
  81. ncbi request reprint Renal cell carcinoma: a priority malignancy for development and study of novel therapies
    Robert J Motzer
    J Clin Oncol 21:1193-4. 2003
  82. ncbi request reprint Adjuvant chemotherapy for stage II nonseminomatous germ-cell tumors
    G Varuni Kondagunta
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Semin Urol Oncol 20:239-43. 2002
    ..A prospective trial of 2 cycles of etoposide plus cisplatin adjuvant chemotherapy for patients with pN2 tumors showed that this regimen was highly effective in achieving relapse-free survival...
  83. ncbi request reprint Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma
    Jacqueline Vuky
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Invest New Drugs 20:327-30. 2002
    ....
  84. ncbi request reprint Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastasis on survival
    J James Bruno
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 97:933-8. 2006
    ..To analyse the survival benefit of resecting local recurrence (LR) of renal cell carcinoma (RCC) in the presence and absence of concomitant metastasis...
  85. ncbi request reprint Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection
    Brett S Carver
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Urol 176:100-3; discussion 103-4. 2006
    ..We evaluated patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell tumors to determine predictors of teratomatous elements in the retroperitoneum...
  86. ncbi request reprint Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence
    Scott E Eggener
    Genitourinary Oncology Service, Division of Solid Tumor Oncology and Department of Urology, Memorial Sloan Kettering Cancer Center, 353 E 68th St, New York, NY 10021, USA
    J Clin Oncol 24:3101-6. 2006
    ..Prognostic factors for patients with metastatic renal cell carcinoma (RCC) are well established. However, the risk profile is unknown for patients with recurrent RCC after a nephrectomy for localized disease...
  87. ncbi request reprint Sunitinib efficacy against advanced renal cell carcinoma
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 178:1883-7. 2007
    ..We assessed the efficacy of the oral multitargeted tyrosine kinase inhibitor sunitinib in patients with metastatic clear cell renal cell carcinoma...
  88. ncbi request reprint Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib
    Darren R Feldman
    J Natl Cancer Inst 99:974-5; author reply 976-7. 2007
  89. ncbi request reprint Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    Gary Hudes
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    N Engl J Med 356:2271-81. 2007
    ..Interferon alfa is widely used for metastatic renal-cell carcinoma but has limited efficacy and tolerability. Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, may benefit patients with this disease...
  90. ncbi request reprint Adjuvant chemotherapy for stage II nonseminomatous germ cell tumors
    G Varuni Kondagunta
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Urol Clin North Am 34:179-85; abstract ix. 2007
    ..In contrast, patients who have high-volume nodal involvement at RPLND have a relapse rate of 50% to 90% with surveillance alone, and adjuvant chemotherapy is the preferable option in this group...
  91. ncbi request reprint Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour
    Bobby Shayegan
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 99:993-7. 2007
    ....
  92. ncbi request reprint Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma
    Satish K Tickoo
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 177:1258-63. 2007
    ..We investigated the hypoxia inducible pathway marker immunohistochemical expression profile, and any potential therapeutic implications that such expression may have, in these tumors...
  93. ncbi request reprint Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer
    Scott E Eggener
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 177:937-42; discussion 942-3. 2007
    ..We evaluated the incidence, sites and histology of disease outside 5 modified retroperitoneal lymph node dissection templates for patients with low stage nonseminomatous germ cell tumors of the testis...
  94. ncbi request reprint Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma
    Brett S Carver
    Department of Urology and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 25:1033-7. 2007
    ..We evaluated patients at our institution undergoing initial PC-RPLND for teratoma to determine their clinical outcome...
  95. ncbi request reprint Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors
    G Varuni Kondagunta
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:85-90. 2007
    ..This prospective trial followed a similarly designed report of TICE, which used a different means of carboplatin dosing...
  96. ncbi request reprint Targeting von Hippel-Lindau pathway in renal cell carcinoma
    Premal H Patel
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 12:7215-20. 2006
    ....
  97. ncbi request reprint Testicular cancer. Clinical practice guidelines in oncology
    Robert J Motzer
    J Natl Compr Canc Netw 4:1038-58. 2006
  98. ncbi request reprint Treatment outcome for metastatic papillary renal cell carcinoma patients
    Ellen A Ronnen
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 107:2617-21. 2006
    ..The current retrospective study sought to define clinical features and outcome data for metastatic papillary RCC...
  99. ncbi request reprint Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma
    Revathi Suppiah
    Department of Hematology and Oncology, Cleveland Clinic Foundation, Taussig Cancer Center, Cleveland, Ohio 44195, USA
    Cancer 107:1793-800. 2006
    ..It has been suggested that thrombocytosis, as defined by a platelet count >400,000/microL, is a negative predictor for survival among patients with metastatic renal cell carcinoma. However, this has not been a uniform finding...
  100. ncbi request reprint Long-term response with sunitinib for metastatic renal cell carcinoma
    Ellen A Ronnen
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 68:672.e19-20. 2006
    ..This case report illustrates the long-term response to sunitinib for patients with metastatic renal cell carcinoma...
  101. ncbi request reprint Salvage chemotherapy for patients with advanced pure seminoma
    Jacqueline Vuky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 20:297-301. 2002
    ..We describe the response to conventional or high-dose salvage chemotherapy in patients with advanced seminoma who experience disease progression after receiving first-line platinum-based treatment...

Research Grants6

  1. CLINICAL TRIALS AND MENTORING IN ONCOLOGY RESEARCH
    Robert Motzer; Fiscal Year: 2003
    ..One recently joined staff at MSKCC in the Genito-urinary Section. Mentoring of clinical trials is extended beyond fellowship to junior faculty members. ..
  2. Molecular Basis Of Renal Cell Carcinoma Response to SU11428
    Robert Motzer; Fiscal Year: 2007
    ..These tumor and cell line-based studies lay a foundation for further molecular studies aimed at understanding the sensitivity/resistance of RCC to SU11248. [unreadable] [unreadable] [unreadable]..
  3. Molecular Basis Of Renal Cell Carcinoma Response to SU11428
    Robert Motzer; Fiscal Year: 2008
    ..These tumor and cell line-based studies lay a foundation for further molecular studies aimed at understanding the sensitivity/resistance of RCC to SU11248. ..
  4. Molecular Basis Of Renal Cell Carcinoma Response to SU11428
    Robert Motzer; Fiscal Year: 2009
    ..These tumor and cell line-based studies lay a foundation for further molecular studies aimed at understanding the sensitivity/resistance of RCC to SU11248. ..
  5. Molecular Basis Of Renal Cell Carcinoma Response to SU11428
    Robert J Motzer; Fiscal Year: 2010
    ..These tumor and cell line-based studies lay a foundation for further molecular studies aimed at understanding the sensitivity/resistance of RCC to SU11248. ..
  6. Molecular Basis Of Renal Cell Carcinoma Response to SU11428
    Robert J Motzer; Fiscal Year: 2011
    ..These tumor and cell line-based studies lay a foundation for further molecular studies aimed at understanding the sensitivity/resistance of RCC to SU11248. ..